AstraZeneca Partners with Quell for $2 Billion Cell Therapy Development Agreement

AstraZeneca and Quell Therapeutics have entered into a significant agreement, valued at over $2 billion, to collaborate on the development of cell therapies for the treatment of autoimmune diseases.

This partnership aims to create innovative treatments that could potentially provide a cure for conditions such as type 1 diabetes and inflammatory bowel disease.

Under the terms of the agreement, AstraZeneca will provide an upfront payment of $85 million to Quell, with the potential for additional payments exceeding $2 billion based on the achievement of development and commercialization milestones.